InvestorsHub Logo
Followers 30
Posts 4127
Boards Moderated 0
Alias Born 07/25/2007

Re: None

Friday, 06/03/2022 12:21:11 PM

Friday, June 03, 2022 12:21:11 PM

Post# of 8504
Here is a link to the FDA document, which was provided by Mouton29 on the Biotech Values board.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169046552

It is depressing. The efficacy was good. The side-effects after the first dose wasn't an issue fine but what is troubling is the jump in grade 3 side effects after the second dose. I sold off 2/3 of my position based on that.

It may be that the FDA wasn't as aware or concerned about side-effect after the low incidence of myocarditis in mRNA vaccines than when they were approved. I looked up the incidence of myocarditis in mRNA vaccines but it is ~1 per 100,000, which is an order of magnitude lower than this reports says for NVAX.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVAX News